Q fever seroprevalence in parturient women: the EQRUN cross-sectional study on Reunion Island.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
03 Apr 2020
Historique:
received: 18 03 2019
accepted: 12 03 2020
entrez: 5 4 2020
pubmed: 5 4 2020
medline: 28 5 2020
Statut: epublish

Résumé

Q fever (Coxiella burnetii infection) has been associated with adverse perinatal outcomes. After investigating the obstetrical importance of Q fever on Reunion island and demonstrating an association between incident Q fever and miscarriage, we conducted a cross-sectional serosurvey to assess the prevalence of Coxiella burnetii infection among parturient women. Between January 9 and July 24, 2014, within the level-4 maternity of Saint Pierre hospital and the level-1 maternity of Le Tampon, we proposed to screen all parturient women for Coxiella burnetii serology. Seropositivity was defined using indirect immunofluorescence for a dilution of phase 2 IgG titre ≥1:64. Further dilutions were chosen to discriminate recent or active infections from past or prevalent infections (< 1:128) and classify these as either possible (1:128), or probable (≥1:256). Recurrent miscarriage, stillbirth, preterm birth, small-for-gestational as well as a composite outcome of these adverse pregnancy outcomes were compared according to seropositivity using bivariate analysis or propensity score matching of seropositive and seronegative women on confounding factors. Among 1112 parturient women screened for Q fever over this 7-month period, 203 (18.3%) were seropositive. Overall weighted seroprevalence was of 20.1% (95%CI, 17.7-22.5%). Weighted seroprevalence of probable infections was 4.7% (95%CI 3.4-5.9%), while > 90% of positive serologies corresponded to past infections or false positives. Seropositivity was associated with none of the abovementioned adverse perinatal outcomes, whether in unpaired or matched analyses on propensity score. The magnitude and the pattern of seroprevalence suggest that Q fever is endemic on Reunion island. In this context, we found no significant contribution of prevalent Coxiella burnetii infection to adverse pregnancy outcomes. Although reassuring, these data put in our endemic context, with a previously demonstrated increased risk of incident Q fever associated miscarriage, encourage us to protect pregnant women against the risk of new infection, periconceptional or early in pregnancy.

Sections du résumé

BACKGROUND BACKGROUND
Q fever (Coxiella burnetii infection) has been associated with adverse perinatal outcomes. After investigating the obstetrical importance of Q fever on Reunion island and demonstrating an association between incident Q fever and miscarriage, we conducted a cross-sectional serosurvey to assess the prevalence of Coxiella burnetii infection among parturient women.
METHODS METHODS
Between January 9 and July 24, 2014, within the level-4 maternity of Saint Pierre hospital and the level-1 maternity of Le Tampon, we proposed to screen all parturient women for Coxiella burnetii serology. Seropositivity was defined using indirect immunofluorescence for a dilution of phase 2 IgG titre ≥1:64. Further dilutions were chosen to discriminate recent or active infections from past or prevalent infections (< 1:128) and classify these as either possible (1:128), or probable (≥1:256). Recurrent miscarriage, stillbirth, preterm birth, small-for-gestational as well as a composite outcome of these adverse pregnancy outcomes were compared according to seropositivity using bivariate analysis or propensity score matching of seropositive and seronegative women on confounding factors.
RESULTS RESULTS
Among 1112 parturient women screened for Q fever over this 7-month period, 203 (18.3%) were seropositive. Overall weighted seroprevalence was of 20.1% (95%CI, 17.7-22.5%). Weighted seroprevalence of probable infections was 4.7% (95%CI 3.4-5.9%), while > 90% of positive serologies corresponded to past infections or false positives. Seropositivity was associated with none of the abovementioned adverse perinatal outcomes, whether in unpaired or matched analyses on propensity score.
CONCLUSION CONCLUSIONS
The magnitude and the pattern of seroprevalence suggest that Q fever is endemic on Reunion island. In this context, we found no significant contribution of prevalent Coxiella burnetii infection to adverse pregnancy outcomes. Although reassuring, these data put in our endemic context, with a previously demonstrated increased risk of incident Q fever associated miscarriage, encourage us to protect pregnant women against the risk of new infection, periconceptional or early in pregnancy.

Identifiants

pubmed: 32245372
doi: 10.1186/s12879-020-04969-w
pii: 10.1186/s12879-020-04969-w
pmc: PMC7118902
doi:

Substances chimiques

Antibodies, Bacterial 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

261

Subventions

Organisme : GIRCI SOHO, APIDOM grant 2012
ID : None

Références

Am J Obstet Gynecol. 2003 Jul;189(1):228-32
pubmed: 12861167
Emerg Infect Dis. 2011 Dec;17(12):2360-3
pubmed: 22172140
BMC Infect Dis. 2011 Feb 11;11:44
pubmed: 21314933
Clin Microbiol Rev. 2017 Jan;30(1):115-190
pubmed: 27856520
Clin Diagn Lab Immunol. 1994 Mar;1(2):189-96
pubmed: 7496944
Euro Surveill. 2013 Jul 11;18(28):
pubmed: 23870098
BMJ. 2018 Oct 31;363:k4431
pubmed: 30381296
Epidemiol Infect. 2019 Jan;147:e191
pubmed: 31364550
Am J Trop Med Hyg. 2014 Sep;91(3):642-4
pubmed: 24914001
Obstet Gynecol. 2004 Jun;103(6):1294-9
pubmed: 15172867
Lancet Infect Dis. 2017 Sep;17(9):957-964
pubmed: 28845800
Heliyon. 2018 May 10;4(5):e00615
pubmed: 29872753
Reproduction. 2013 Oct 01;146(5):R151-62
pubmed: 23884862
Lancet. 2006 Feb 25;367(9511):679-88
pubmed: 16503466
Epidemiol Infect. 2018 Jun;146(8):1056-1064
pubmed: 29720285
PLoS One. 2012;7(2):e31909
pubmed: 22363769
BMC Infect Dis. 2013 Feb 17;13:87
pubmed: 23413787
Clin Microbiol Infect. 2012 Jun;18(6):533-8
pubmed: 22471505
Emerg Infect Dis. 2014 Jun;20(6):925-31
pubmed: 24856281
PLoS Negl Trop Dis. 2014 Aug 07;8(8):e3055
pubmed: 25101780
Open Forum Infect Dis. 2019 May 15;6(7):ofz227
pubmed: 31281854
BMC Res Notes. 2019 Jul 9;12(1):387
pubmed: 31288833
Clin Infect Dis. 2007 Sep 1;45(5):548-55
pubmed: 17682987
BMC Infect Dis. 2019 Nov 27;19(1):1001
pubmed: 31775645
Arch Gynecol Obstet. 2016 Aug;294(2):233-8
pubmed: 26559421
Clin Microbiol Infect. 2009 May;15(5):499-501
pubmed: 19489927
Clin Infect Dis. 2014 Jul 15;59(2):256-60
pubmed: 24748522
Eur J Obstet Gynecol Reprod Biol. 2000 Dec;93(2):151-6
pubmed: 11074136

Auteurs

Julien Jaubert (J)

Laboratoire de Bactériologie, Virologie et Parasitologie, Centre Hospitalier Universitaire (CHU) de la Réunion, Saint Pierre, Reunion, France.

Laura Atiana (L)

Laboratoire de Bactériologie, Virologie et Parasitologie, Centre Hospitalier Universitaire (CHU) de la Réunion, Saint Pierre, Reunion, France.

Sophie Larrieu (S)

CIRE Océan Indien, Santé Publique France, French National Public Health Agency, Saint Denis, Reunion, France.

Philippe De Vos (P)

Maternité, Clinique Durieux, Le Tampon, Reunion, France.

Claudine Somon-Payet (C)

Maternité, Pôle Femme Mère Enfant, CHU de la Réunion, St Pierre, Reunion, France.

Sylvaine Porcherat (S)

INSERM CIC 1410 Epidémiologie Clinique, Centre Hospitalier Universitaire, Groupe Hospitalier Sud Réunion, CHU Réunion, BP 350, 97448, Saint Pierre, Cedex-Reunion, France.

Yoan Mboussou (Y)

Laboratoire de Bactériologie, Virologie et Parasitologie, Centre Hospitalier Universitaire (CHU) de la Réunion, Saint Pierre, Reunion, France.

Florence Naze (F)

Laboratoire de Bactériologie, Virologie et Parasitologie, Centre Hospitalier Universitaire (CHU) de la Réunion, Saint Pierre, Reunion, France.

Sandrine Picot (S)

Laboratoire de Bactériologie, Virologie et Parasitologie, Centre Hospitalier Universitaire (CHU) de la Réunion, Saint Pierre, Reunion, France.

Malik Boukerrou (M)

Maternité, Pôle Femme Mère Enfant, CHU de la Réunion, St Pierre, Reunion, France.
CEPOI-EA7388, Pôle Femme Mère Enfant, CHU de la Réunion, Saint Pierre, Reunion, France.

Pierre-Yves Robillard (PY)

Maternité, Pôle Femme Mère Enfant, CHU de la Réunion, St Pierre, Reunion, France.
CEPOI-EA7388, Pôle Femme Mère Enfant, CHU de la Réunion, Saint Pierre, Reunion, France.

Patrick Gérardin (P)

INSERM CIC 1410 Epidémiologie Clinique, Centre Hospitalier Universitaire, Groupe Hospitalier Sud Réunion, CHU Réunion, BP 350, 97448, Saint Pierre, Cedex-Reunion, France. patrick.gerardin@chu-reunion.fr.
UM 134 PIMIT Processus Infectieux en Milieu Insulaire Tropical, Université de La Réunion, INSERM 1187, CNRS 9192, IRD 249, CYROI, Sainte Clotilde, Reunion, France. patrick.gerardin@chu-reunion.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH